Kfir Schreiber is the Co-Founder and CEO of DeepCure, a cutting-edge biotechnology company focused on transforming drug discovery through advanced artificial intelligence. With a strong foundation in machine learning, artificial intelligence, and bioinformatics, Kfir is committed to developing novel therapeutic solutions to address unmet medical needs. Before founding DeepCure in 2018, Kfir worked as a Research Assistant at the Massachusetts Institute of Technology (MIT) Media Lab, where he gained invaluable experience in AI applications within the life sciences. His military service as an officer in the Israeli Air Force further honed his leadership skills and strategic thinking. Kfir holds a Master of Science in Machine Learning, Artificial Intelligence, and Bioinformatics from MIT, as well as a Master of Science in Applied Mathematics from Tel Aviv University. Under his leadership, DeepCure has made significant strides, including recent presentations showcasing their selective BRD4 (BD2) inhibitor, DC-9476, which demonstrates superior efficacy in preclinical models of rheumatoid arthritis and macrophage activation syndrome.